Ionis Pharmaceuticals (IONS) Set to Announce Quarterly Earnings on Tuesday

Ionis Pharmaceuticals (NASDAQ:IONS) is scheduled to release its earnings data before the market opens on Tuesday, May 7th. Analysts expect Ionis Pharmaceuticals to post earnings of ($1.07) per share for the quarter. Ionis Pharmaceuticals has set its FY 2024 guidance at EPS.Persons that are interested in registering for the company’s earnings conference call can do so using this link.

Ionis Pharmaceuticals (NASDAQ:IONS) last announced its earnings results on Wednesday, February 21st. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.72. The business had revenue of $325.00 million for the quarter, compared to the consensus estimate of $176.01 million. Ionis Pharmaceuticals had a negative return on equity of 90.29% and a negative net margin of 46.32%. Ionis Pharmaceuticals’s revenue was up 113.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.37) EPS. On average, analysts expect Ionis Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Ionis Pharmaceuticals Trading Down 2.6 %

Ionis Pharmaceuticals stock opened at $41.97 on Monday. The business’s fifty day moving average is $43.07 and its two-hundred day moving average is $46.99. The company has a debt-to-equity ratio of 3.18, a current ratio of 5.90 and a quick ratio of 5.83. Ionis Pharmaceuticals has a 52 week low of $34.32 and a 52 week high of $54.44.

Insider Buying and Selling

In other Ionis Pharmaceuticals news, EVP Joseph Baroldi sold 4,006 shares of the company’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $41.60, for a total value of $166,649.60. Following the completion of the sale, the executive vice president now owns 19,631 shares of the company’s stock, valued at $816,649.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.65% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

IONS has been the topic of several research reports. Piper Sandler upped their price objective on Ionis Pharmaceuticals from $62.00 to $63.00 and gave the stock an “overweight” rating in a report on Thursday, February 22nd. JPMorgan Chase & Co. upped their price target on Ionis Pharmaceuticals from $52.00 to $55.00 and gave the company a “neutral” rating in a research note on Thursday, February 1st. William Blair reiterated an “outperform” rating on shares of Ionis Pharmaceuticals in a research report on Tuesday, April 9th. Wolfe Research raised Ionis Pharmaceuticals from a “peer perform” rating to an “outperform” rating and set a $58.00 price objective for the company in a report on Wednesday, April 10th. Finally, Oppenheimer raised their target price on shares of Ionis Pharmaceuticals from $72.00 to $75.00 and gave the company an “outperform” rating in a research note on Tuesday, April 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $57.67.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.